Shares of Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) saw unusually-strong trading volume on Tuesday. Approximately 2,556,335 shares changed hands during trading, an increase of 493% from the average daily volume of 430,965 shares. The stock last traded at $7.30 and had previously closed at $7.54.
Analysts Set New Price Targets
Separately, Barclays raised Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.
Get Our Latest Stock Analysis on CLPBY
Coloplast A/S Trading Up 1.0%
The stock has a market capitalization of $16.65 billion, a P/E ratio of 35.19, a PEG ratio of 3.56 and a beta of 0.10. The stock’s fifty day moving average price is $6.87 and its 200 day moving average price is $6.77. The company has a debt-to-equity ratio of 1.51, a current ratio of 1.56 and a quick ratio of 0.94.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. Coloplast A/S had a net margin of 10.57% and a return on equity of 42.25%. Research analysts forecast that Coloplast A/S Sponsored ADR will post 0.37 earnings per share for the current year.
About Coloplast A/S
Coloplast A/S is a Danish medical device company that develops and markets products and services for people with intimate health care needs. Its main business areas include ostomy care, continence care, wound and skin care, and urology care. Its products include ostomy bags and accessories, catheters and other continence products, wound dressings, and devices used in urological procedures. Coloplast also provides voice and respiratory care products, including solutions for people who have had a laryngectomy.
Featured Stories
- Five stocks we like better than Coloplast A/S
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
